Undisclosed In Vivo Program
Sickle Cell Disease (SCD)
Key Facts
About Editas Medicine
Editas Medicine is a leader in the CRISPR gene editing space, aiming to discover, develop, manufacture, and commercialize a robust pipeline of genomic medicines. The company leverages two distinct CRISPR nucleases, Cas9 and Cas12a, to access a broad range of genetic mutations and develop targeted in vivo therapies. Its strategic focus includes hemoglobinopathies, in vivo editing of hematopoietic stem cells and liver, and advancing cellular therapy assets through key partnerships with Bristol-Myers Squibb and Immatics N.V.
View full company profileAbout Editas Medicine
Editas Medicine is a leader in the CRISPR gene editing space, aiming to discover, develop, manufacture, and commercialize a robust pipeline of genomic medicines. The company leverages two distinct CRISPR nucleases, Cas9 and Cas12a, to access a broad range of genetic mutations and develop targeted in vivo therapies. Its strategic focus includes hemoglobinopathies, in vivo editing of hematopoietic stem cells and liver, and advancing cellular therapy assets through key partnerships with Bristol-Myers Squibb and Immatics N.V.
View full company profileTherapeutic Areas
Other Sickle Cell Disease (SCD) Drugs
| Drug | Company | Phase |
|---|---|---|
| CASGEVY (exagamglogene autotemcel/exa-cel) | CRISPR Therapeutics | Approved |